Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Treatment: biologics
View through CrossRef
According to classification criteria, the spectrum of spondyloarthritis (SpA) covers axial SpA (axSpA), which includes non-radiographic axSpA and ankylosing spondylitis, and peripheral SpA, which overlaps with psoriatic arthritis. Management recommendations for many forms of SpA have been recently published. Treatment of patients with axSpA with active disease starts with a sufficient dose of non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks and preferably longer, in combination with exercise. In case of peripheral SpA, several disease-modifying antirheumatic drugs can be given, but these are not efficacious in axial disease. In case of insufficient response to NSAIDs for axSpA, biologic treatment can be added. The biologics most commonly used are TNF-blocking agents, but some other biologic agents seem to be beneficial in axial diseases as well, such as secukinumab (an IL-17 blocker). However, these new drugs have not yet been approved for axSpA at the time of writing this chapter.
Title: Treatment: biologics
Description:
According to classification criteria, the spectrum of spondyloarthritis (SpA) covers axial SpA (axSpA), which includes non-radiographic axSpA and ankylosing spondylitis, and peripheral SpA, which overlaps with psoriatic arthritis.
Management recommendations for many forms of SpA have been recently published.
Treatment of patients with axSpA with active disease starts with a sufficient dose of non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks and preferably longer, in combination with exercise.
In case of peripheral SpA, several disease-modifying antirheumatic drugs can be given, but these are not efficacious in axial disease.
In case of insufficient response to NSAIDs for axSpA, biologic treatment can be added.
The biologics most commonly used are TNF-blocking agents, but some other biologic agents seem to be beneficial in axial diseases as well, such as secukinumab (an IL-17 blocker).
However, these new drugs have not yet been approved for axSpA at the time of writing this chapter.
Related Results
Dual diagnosis
Dual diagnosis
Substance abuse and mental illness are concentrated in correctional populations. Further, nearly half of female inmates and one-third of male inmates with substance use disorders h...
Values-Based Involuntary Seclusion and Treatment
Values-Based Involuntary Seclusion and Treatment
This chapter gives a reflective account of a values-based model of involuntary psychiatric seclusion and treatment (henceforth “involuntary treatment”) adopted in the training mate...
Coercion in Community Mental Health Care
Coercion in Community Mental Health Care
The use of coercion is one of the defining issues of mental health care and has been intensely controversial since the very earliest attempts to contain and treat the mentally ill....
Empirically Supported Couple Therapies
Empirically Supported Couple Therapies
This article provides a comparative review of five empirically supported couple therapies: traditional behavioral couple therapy (behavioral marital therapy), cognitive behavioral ...
Management of Sickle Cell Pain
Management of Sickle Cell Pain
Abstract
While sickle cell disease (SCD) is uncommon in Europe and North America, SCD patients presenting for pain account for an outsized and prominent proportion o...
Treatment Refusal
Treatment Refusal
Management of treatment refusal can be legally and ethically complicated. Patients may refuse various types of treatment, including medications, group and individual psychotherapy,...
Surgical interventions in the complex treatment of pulmonary tuberculosis. Preoperative planning with 3D modeling
Surgical interventions in the complex treatment of pulmonary tuberculosis. Preoperative planning with 3D modeling
The monograph is devoted to an important medical and social problem - improving the effectiveness of treatment of tuberculosis patients with surgical interventions. Evaluation of t...